Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9880
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Author: Aalbers, R.
Ayres, J.
Backer, V.
Decramer, M.
Lier, P.
Magyar, P.
Malolepszy, J.
Ruffin, R.
Sybrecht, G.
Citation: European Respiratory Journal, 2002; 19(5):936-943
Publisher: Munksgaard Int Publ Ltd
Issue Date: 2002
ISSN: 0903-1936
1399-3003
Statement of
Responsibility: 
R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin and G.W. Sybrecht
Abstract: The aim of this study was to investigate formoterol, an inhaled longacting b2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 mg b.i.d.) or placebo via Turbuhaler1 for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 mg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 mg b.i.d.) significantly reduced symptom scores for breathlessness (-7% and -9%, respectively) and chest tightness (-11% and -8%, respectively), reduced the need for rescue medication (-25% and -18%, respectively), and increased symptomfree days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 mg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 mg b.i.d. and higher.
Keywords: Humans
Pulmonary Disease, Chronic Obstructive
Ethanolamines
Bronchodilator Agents
Exercise Test
Diagnostic Techniques, Respiratory System
Spirometry
Treatment Outcome
Administration, Inhalation
Severity of Illness Index
Double-Blind Method
Time Factors
Aged
Middle Aged
Female
Male
Formoterol Fumarate
Rights: Copyright ©ERS Journals Ltd 2002
DOI: 10.1183/09031936.02.00240902
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.